LIQUID BIOPSY The flexibility of automated extraction


platforms like the chemagic 360 instrument supports this multi-omics vision in part by enabling efficient nucleic acid extraction from various sample types and volumes. The complex, multidimensional data


generated by liquid biopsy research is particularly well-suited for artificial intelligence (AI) approaches. Machine learning algorithms can: 1 Integrate multiple biomarker classes to identify paterns associated with specific cancer phenotypes


2 Detect subtle signals in cfDNA fragmentation or methylation paterns that human analysis might miss


3 Predict tumour evolution trajectories based on longitudinal liquid biopsy data


4 Identify novel biomarkers by analysing large datasets without prior hypotheses.


Early research using AI-enhanced liquid biopsy has shown promising results.4 For example, deep learning approaches analysing cfDNA methylation paterns have identified cancer-specific signatures across multiple tumour types with high accuracy, suggesting potential for pan- cancer classification systems. While cancer has been the primary


focus of liquid biopsy research, the principles and technologies developed in this field are increasingly being applied to other diseases. Cell-free DNA analysis is being explored in autoimmune disorders, infectious diseases, transplant rejection monitoring, and neurodegenerative conditions.


This expansion reflects a broader


recognition that circulating nucleic acids can provide valuable insights into diverse pathological processes. The methodological advances driven by cancer research – including improved extraction techniques, error-suppression sequencing, and computational analysis tools – are creating a foundation for liquid biopsy applications across medicine.


Conclusions Liquid biopsy represents one of the most significant technological advances in cancer research in recent decades. By enabling non-invasive, real-time molecular profiling of tumours, this approach has transformed our understanding of cancer biology, heterogeneity, evolution, and treatment response.1,2


Cell-free DNA


analysis has emerged as a versatile and powerful tool with diverse research applications across cancer types. The rapid technological evolution in this field continues to improve sensitivity, specificity, and throughput while driving


2


While cancer has been the primary focus of liquid biopsy research, the principles and technologies developed in this field are increasingly being applied to other diseases.


down costs. Automated extraction solutions like the chemagic cfDNA kits and chemagic 360 instrument are playing an important role in this evolution, addressing pre-analytical challenges that have historically limited large-scale liquid biopsy research. By providing consistent, high-quality cfDNA from various sample types and volumes, these technologies are helping to standardise workflows and improve reproducibility across research laboratories.5 As liquid biopsy technologies continue


to advance, they promise to further bridge the gap between basic cancer biology and clinical applications, accelerating the pace of discovery and translation. The ability to monitor cancer non- invasively and comprehensively through simple blood draws is revolutionising not only how we study cancer but also how we conceptualise the disease itself – as a dynamic, evolving entity that requires equally dynamic approaches to investigation and intervention.


References 1 Wan JCM, Massie C, Garcia-Corbacho J,


et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223-238. doi:10.1038/nrc.2017.7


Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531-548. doi:10.1038/ nrclinonc.2017.14


3 Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451. doi:10.1038/ nature22364


4 Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV; CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745- 759. doi:10.1016/j.annonc.2020.02.011


5 Revvity. Technical note: Automated circulating cell-free DNA purification with the chemagic 360 instrument. (Revvity, 2023) htps://www.revvity.com/de-en/ content/automated-circulating-cell-free- dna-purification-chemagic-360-instrument


6 Pallisgaard N. The fascinating world of cell-free DNA (cfDNA) isolation and digital PCR analysis - webinar. (Revvity, 2023) htps://www.revvity.com/de-en/content/ fascinating-world-cell-free-dna-cfdna- isolation-and-digital-pcr-analysis


PPi


Dr Uwe Jäntges serves as Senior Portfolio Director at Revvity, leading the Automated Nucleic Acid Purification Products portfolio. With over 20 years of expertise in laboratory automation and genomic testing applications within clinical research, Dr Jäntges has deep technical knowledge and industry insights. He earned his PhD in Biotechnology from


RWTH Aachen University, providing him with a strong scientific foundation that complements his extensive practical experience in advancing automated solutions for nucleic acid workflows.


www.revvity.com February 2026 WWW.PATHOLOGYINPRACTICE.COM 29


AdobeStock / arcyto


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56